Neurobehavioral Challenges in Developmental Epileptic Encephalopathies
Program Overview
Developmental and epileptic encephalopathies (DEEs) are devastating conditions marked by treatment-resistant seizures and significant comorbid neurodevelopmental challenges for which there continues to be a significant clinical, humanistic, and economic unmet need. As part of those neurodevelopmental challenges, many children clinically present with autistic tendencies and traits, elements of autism spectrum disorder (ASD). This activity reviews the latest understanding of these behavioral challenges, including genetic correlates, clinical characteristics, and behavior management strategies.
Target Audience
This activity is intended for health care professionals engaged in the care of patients with epilepsy.
Educational Objectives
After completing this activity, the participant should be better able to:
- Discuss the epidemiology, clinical presentation, and burden of autism spectrum disorder (ASD) in epileptic encephalopathies (EEs)
- Analyze the key neuroanatomical and molecular determinants that regulate the complexities of behavior associated with epilepsy and EEs
- Examine the relationship between seizure frequency and executive functions, such as behavior, emotion, and cognition
- Discuss current and emerging behavioral and pharmacologic management approaches for the treatment of ASD in EEs
Agenda
| 12:30 pm – 12:50 pm |
The Association of Autistic Spectrum Disorder (ASD) and Epileptic Encephalopathies (EEs) |
| 12:50 pm – 1:10 pm |
Genetics and Neurodevelopment Relationship of ASD and EEs |
| 1:10 pm – 1:30 pm |
Clinical Presentation and Behavior Management |
| 1:30 pm – 1:45 pm |
Q&A |
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
| Faculty | Relationship Identified With: |
|---|---|
| Rima Nabbout, MD, PhD |
Disclosed the following relevant financial relationships: Consulting Fees from Biogen, Eisai, Encoded Therapeutics, GW Pharmaceuticals, ICON, IONIS Pharmaceuticals, Lundbeck, Stoke Therapeutics, Supernus Pharmaceuticals Fees for non-CME/CE services received directly from a commercial interest or their Agents (eg, speakers’ bureaus) from Advicenne, Biocodex, GW Pharmaceuticals, Nutricia, Shire, UCB, Zogenix Contracted Research for GW Pharmaceuticals, Zogenix |
| Rodney C. Samaco, PhD |
Disclosed the following relevant financial relationships: Fees for non-CME/CE services received directly from a commercial interest or their Agents (eg, speakers’ bureaus) from Global Genes Contracted Research for Ultragenyx Pharmaceutical |
| Shannon M. Standridge, DO, MPH |
Disclosed the following relevant financial relationships: Consulting Fees from ACADIA Pharmaceuticals Inc, Zogenix Fees for non-CME/CE services received directly from a commercial interest or their Agents (eg, speakers’ bureaus) from Greenwich Biosciences, Inc |
Planners and Managers
The PIM planners and managers have nothing to disclose. The Miller Medical Communications, LLC, planners and managers have nothing to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Miller Medical Communications, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Information
Jointly provided by Postgraduate Institute for Medicine and Miller Medical Communications, LLC.
Financial Support
This activity is supported by an independent educational grant from Zogenix, Inc.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Media
Internet
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation and Request for Credit
- There are no fees for participating in and receiving CME/CE credit for this activity. During the period October 15, 2020, through December 31, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.
- If you wish to receive acknowledgment for completing this activity, please complete the evaluation.
- Upon registering and successfully completing the activity evaluation, your certificate will be made available immediately.
Contact Information for Questions About the Activity
Kat Golden,
kat.golden@millermeded.com, 212-661-7400, ext. 8
Jennifer Kunst, jkunst@pimed.com, 720-895-5333, www.pimed.com
System Requirements
Performedia requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software.
Release date: October 21, 2020, 12:30pm – 1:45pm PDT
Expiration date: December 31, 2020
Estimated time to completion: 1.25 hours